OncoMatch/Clinical Trials/NCT06208826
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Is NCT06208826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Toripalimab and Cisplatin for head and neck cancer.
Treatment: Toripalimab · Cisplatin — Head and neck cancer is the malignant tumor with the highest morbidity and mortality, of which 60% present with locally advanced disease at initial diagnosis, and the 5-year survival rate of standard treatment is less than 30%. Standard of care (SOC) including adjuvant and neoadjuvant therapy can provides only about 5-10% clinical benefit. According to the available data on the application of immunotherapy as adjuvant therapy in operable patients, adjuvant immunotherapy is safe and feasible, with a significant trend of benefit. Based on the above positive and meaningful clinical needs and scientific basis, it is very necessary to carry out clinical trials of adjuvant immunotherapy. The primary objective of this study is to evaluate the efficacy and safety of immune maintenance therapy in patients with locally advanced head and neck squamous cell carcinoma who achieve MPR after neoadjuvant immunotherapy combined with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: immunotherapy — neoadjuvant
Achievement of major pathological response (MPR) after surgery with neoadjuvant immunotherapy combined chemotherapy
Must have received: chemotherapy — neoadjuvant
Achievement of major pathological response (MPR) after surgery with neoadjuvant immunotherapy combined chemotherapy
Cannot have received: investigational drug
Received any investigational drug within 4 weeks prior to the first dose
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10^9/l, hemoglobin ≥ 9.0g/dl, platelets ≥100000/μl
Kidney function
creatinine clearance ≥ 60 ml/min
Liver function
alt and ast < 2.5× uln, total bilirubin ≤ 1.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06208826 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational drug disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages